These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29496049)

  • 1. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
    Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
    Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
    Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
    Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
    Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
    Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.
    Dong S; Zhao M; Zhu J; Li T; Yan M; Xing K; Liu P; Yu S; Ma J; He H
    Front Immunol; 2024; 15():1442673. PubMed ID: 39234249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
    Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
    Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
    Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.
    Luo X; Donnelly CR; Gong W; Heath BR; Hao Y; Donnelly LA; Moghbeli T; Tan YS; Lin X; Bellile E; Kansy BA; Carey TE; Brenner JC; Cheng L; Polverini PJ; Morgan MA; Wen H; Prince ME; Ferris RL; Xie Y; Young S; Wolf GT; Chen Q; Lei YL
    J Clin Invest; 2020 Apr; 130(4):1635-1652. PubMed ID: 31874109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
    Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
    Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cGAS-STING responses are dampened in high-risk HPV type 16 positive head and neck squamous cell carcinoma cells.
    Shaikh MH; Bortnik V; McMillan NA; Idris A
    Microb Pathog; 2019 Jul; 132():162-165. PubMed ID: 31054871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
    Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
    Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
    Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
    Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
    Front Immunol; 2021; 12():737311. PubMed ID: 34557197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.